IRLAB A Stock Overview
IRLAB Therapeutics AB (publ) develops drugs for the treatment of Parkinson’s disease.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
IRLAB Therapeutics AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr10.55 |
| 52 Week High | kr20.20 |
| 52 Week Low | kr5.58 |
| Beta | 0.46 |
| 1 Month Change | -39.71% |
| 3 Month Change | -24.10% |
| 1 Year Change | -1.40% |
| 3 Year Change | -72.24% |
| 5 Year Change | -85.06% |
| Change since IPO | -10.59% |
Recent News & Updates
Recent updates
Here's Why We're Watching IRLAB Therapeutics' (STO:IRLAB A) Cash Burn Situation
Jan 04
Here's Why IRLAB Therapeutics (STO:IRLAB A) Must Use Its Cash Wisely
Sep 21We Think IRLAB Therapeutics (STO:IRLAB A) Needs To Drive Business Growth Carefully
Mar 18IRLAB Therapeutics (STO:IRLAB A) Is In A Good Position To Deliver On Growth Plans
Dec 01We Like IRLAB Therapeutics' (STO:IRLAB A) Earnings For More Than Just Statutory Profit
May 19We're Interested To See How IRLAB Therapeutics (STO:IRLAB A) Uses Its Cash Hoard To Grow
Sep 11We're Interested To See How IRLAB Therapeutics (STO:IRLAB A) Uses Its Cash Hoard To Grow
Apr 30What Is The Ownership Structure Like For IRLAB Therapeutics AB (publ) (STO:IRLAB A)?
Mar 19We Think IRLAB Therapeutics (STO:IRLAB A) Can Afford To Drive Business Growth
Jan 25Our View On IRLAB Therapeutics' (STO:IRLAB A) CEO Pay
Dec 21What Is The Ownership Structure Like For IRLAB Therapeutics AB (publ) (STO:IRLAB A)?
Nov 25
Shareholder Returns
| IRLAB A | SE Pharmaceuticals | SE Market | |
|---|---|---|---|
| 7D | -23.6% | -3.0% | 0.9% |
| 1Y | -1.4% | 60.0% | 10.3% |
Return vs Industry: IRLAB A underperformed the Swedish Pharmaceuticals industry which returned 60% over the past year.
Return vs Market: IRLAB A underperformed the Swedish Market which returned 10.7% over the past year.
Price Volatility
| IRLAB A volatility | |
|---|---|
| IRLAB A Average Weekly Movement | 14.1% |
| Pharmaceuticals Industry Average Movement | 6.3% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in SE Market | 13.0% |
| 10% least volatile stocks in SE Market | 3.5% |
Stable Share Price: IRLAB A's share price has been volatile over the past 3 months.
Volatility Over Time: IRLAB A's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 31 | Gunnar Olsson | www.irlab.se |
IRLAB Therapeutics AB (publ) develops drugs for the treatment of Parkinson’s disease. The company develops Mesdopetam that is in phase IIb/III clinical studies for the treatment of dyskinesia; and Pirepemat, which is in phase IIb clinical trial for the treatment of Postural dysfunction. Its preclinical stage products include IRL942 research programs for the treatment of neurodegenerative disorders and ageing; IRL1117, a drug candidate developed for once-daily oral treatment for the hallmark symptoms of Parkinson’s; and IRL757 to treat apathy in neurological diseases.
IRLAB Therapeutics AB (publ) Fundamentals Summary
| IRLAB A fundamental statistics | |
|---|---|
| Market cap | kr547.21m |
| Earnings (TTM) | -kr177.84m |
| Revenue (TTM) | kr5.68m |
96.4x
P/S Ratio-3.1x
P/E RatioIs IRLAB A overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IRLAB A income statement (TTM) | |
|---|---|
| Revenue | kr5.68m |
| Cost of Revenue | kr128.41m |
| Gross Profit | -kr122.73m |
| Other Expenses | kr55.11m |
| Earnings | -kr177.84m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 29, 2024
| Earnings per share (EPS) | -3.43 |
| Gross Margin | -2,161.57% |
| Net Profit Margin | -3,132.07% |
| Debt/Equity Ratio | 21.2% |
How did IRLAB A perform over the long term?
See historical performance and comparison